Last reviewed · How we verify
GKT137831
At a glance
| Generic name | GKT137831 |
|---|---|
| Also known as | NOX1/4 inhibitor, setanaxib |
| Sponsor | Calliditas Therapeutics AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Setanaxib in Patients With Alport Syndrome (PHASE1, PHASE2)
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria (PHASE2)
- GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis (PHASE2)
- Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects (PHASE1)
- Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets (PHASE1)
- Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GKT137831 CI brief — competitive landscape report
- GKT137831 updates RSS · CI watch RSS
- Calliditas Therapeutics AB portfolio CI